- CRISPR Therapeutics (NASDAQ:CRSP) slumps 20% after hours on robust volume in response to its disclosure that the FDA has placed a clinical hold on its IND for sickle cell disease (SCD) gene therapy candidate CTX001. The suspension will be in effect pending the resolution of certain questions related to the application.
- Once approved, a U.S.-based Phase 1/2 study in adult SCD patients will commence. A Phase 1/2 study in adults with transfusion-dependent beta-thalassemia should start in H2 in Europe.
- The company is co-developing the therapy with collaboration partner Vertex Pharmaceuticals (NASDAQ:VRTX).
- SCD-related tickers: (NASDAQ:GBT)(NASDAQ:BLUE)(NYSE:SNY)(NASDAQ:SGMO)(NASDAQ:IRWD)
- Previously: CRISPR Therapeutics and Vertex team up to advance and commercialize lead gene editing candidate for blood disorders (Dec. 12, 2017)
- Now read: Reader Inquiry: Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity?
Original article